About us
Board of Directors
Our Team
Incanthera has an experienced and diverse team, operating a lean business model by outsourcing all development work ensuring a low internal fixed cost model.
Tim McCarthy
Chairman
Dr Simon Ward
Chief Executive Officer
Caroline Murray
Non-Executive Director
Tim has 40 years’ international senior level business experience in the Healthcare, Biotech and Technology sectors.
He is also CEO of ImmuPharma plc an AIM quoted specialist drug discovery and development company and Chairman of 4basebio PLC, an AIM quoted company developing next generation gene therapy technologies and solutions.
Tim is a former CEO and Finance Director of a number of public and private companies, including Alizyme plc and Peptide Therapeutics Group plc. He has also co-founded a number of healthcare and biotechnology companies. A Fellow of the Association of Chartered Certified Accountants, he also has an MBA from Cranfield School of Management.
Close
Simon is a co-founder of Incanthera and has more than 30 years’ senior experience in academia and business.
He was a founder and CEO of Molecular SkinCare Limited, a pioneer and developer of novel dermatology products for the prevention and management of skin diseases. As CSO of York Pharma plc, he was responsible for bringing innovative dermatology product through to market. Simon also served as chairman of South Yorkshire Bioscience Enterprise Network (SYBEN) and deputy chairman of Medipex, a healthcare innovation hub for NHS organisations across industry and academia internationally.
Simon graduated from the University of London’s School of Pharmacy (UK) with a Joint Honours Degree in Pharmacology and Toxicology and was awarded a DPhil in the Department of Human Anatomy, Oxford University under a Glaxo Group Research Studentship.
Close
Caroline’s expertise across healthcare, market positioning and strategic implementation brings extensive product management, and marketing and commercialisation experience to the Board. Senior positions held in the pharmaceutical industry, including both Novartis and Bristol Myers Squibb, over 30 years, combine dermatology, healthcare and commercial skills, perfectly suited to the company’s goals.
Close
Mr John Howes
Senior Independent Director
With more than 43 years’ experience in UK equity capital markets, John brings a wealth of knowledge and Institutional relationships to Stanford Capital Partners. John has extensive experience in the UK equity capital markets building an established reputation in the small and mid-cap sectors, holding previous positions as Partner with Matrix Corporate Capital and senior positions at Seymour Pierce, Panmure Gordon, Northland Capital and Stanford Capital.
Close
Tim McCarthy
Chairman
Tim has 40 years’ international senior level business experience in the Healthcare, Biotech and Technology sectors.
He is also CEO of ImmuPharma plc an AIM quoted specialist drug discovery and development company and Chairman of 4basebio PLC, an AIM quoted company developing next generation gene therapy technologies and solutions.
Tim is a former CEO and Finance Director of a number of public and private companies, including Alizyme plc and Peptide Therapeutics Group plc. He has also co-founded a number of healthcare and biotechnology companies. A Fellow of the Association of Chartered Certified Accountants, he also has an MBA from Cranfield School of Management.
Close
Dr Simon Ward
Chief Executive Officer
Simon is a co-founder of Incanthera and has more than 30 years’ senior experience in academia and business.
He was a founder and CEO of Molecular SkinCare Limited, a pioneer and developer of novel dermatology products for the prevention and management of skin diseases. As CSO of York Pharma plc, he was responsible for bringing innovative dermatology product through to market. Simon also served as chairman of South Yorkshire Bioscience Enterprise Network (SYBEN) and deputy chairman of Medipex, a healthcare innovation hub for NHS organisations across industry and academia internationally.
Simon graduated from the University of London’s School of Pharmacy (UK) with a Joint Honours Degree in Pharmacology and Toxicology and was awarded a DPhil in the Department of Human Anatomy, Oxford University under a Glaxo Group Research Studentship.
Close
Caroline Murray
Non-Executive Director
Caroline’s expertise across healthcare, market positioning and strategic implementation brings extensive product management, and marketing and commercialisation experience to the Board. Senior positions held in the pharmaceutical industry, including both Novartis and Bristol Myers Squibb, over 30 years, combine dermatology, healthcare and commercial skills, perfectly suited to the company’s goals.
Close
Mr John Howes
Senior Independent Director
With more than 43 years’ experience in UK equity capital markets, John brings a wealth of knowledge and Institutional relationships to Stanford Capital Partners. John has extensive experience in the UK equity capital markets building an established reputation in the small and mid-cap sectors, holding previous positions as Partner with Matrix Corporate Capital and senior positions at Seymour Pierce, Panmure Gordon, Northland Capital and Stanford Capital.
Close